Molecular Heart receives over $100 million in financing, with multiple capital sources betting on AI biology as "new industrial infrastructure"
MoleculeMind, an AI protein design platform, has secured over $100 million in Series A funding. The investment, led by Blue Horizon Capital and Pudong Venture Capital, signals a shift in the AI for Science sector towards industrial-scale applications and commercial viability. The company leverages its proprietary AI operating system, MoleculeOS, and its foundational model, NewOrigin, to move beyond basic structure prediction into programmable bioengineering, demonstrating significant advancements in drug discovery and industrial enzyme modification. AI
IMPACT This funding round signifies a major investment in AI for Science, potentially accelerating the development and commercialization of AI-driven solutions in drug discovery and bioengineering.
- AlphaFold 3
- Oriental Fortune Capital
- Fosun Capital
- MoleculeMind
- MMDesign
- Xu Jinbo
- NewOrigin
- MoleculeOS
- Blue Horizon Capital
- SaiFen Technology
- Pudong Venture Capital
- CaiXin Capital
- Kaisai Biological
- COFCO Emerging Industry Fund
- MMFold
- Guofang Venture Capital
- Infinity Capital
- ZhengDing Capital
- Xinhang Capital